Agenus announces first patient dosed in phase 1 study of agen1571 (anti-ilt2) in advanced solid tumors

Study will evaluate safety and tolerability of agen1571 as a single agent and in combination with botensilimab and balstilimab
AGEN Ratings Summary
AGEN Quant Ranking